epocrates logo
epocrates logo
epocrates logo
  • 0

Herbs & Supplements

epocrates logo

Sign in to access our clinical decision support tools

Sign in Create Account

Formulary
No Formulary Selected

close

 

Select a medication above to begin.

astragalus (Astragalus spp.)

common name

Sections:

  • Entire Monograph
  • Reported Uses
  • Reported Doses
  • Cautions
  • Drug Interactions
  • Adverse Reactions
  • Synonyms
  • Other Info
  • Add to Interaction Check

Reported Uses

  • NOTE: see Herb & Supplement Effectiveness Rating Definitions table
  • allergic rhinitis [Insufficient Evidence]
  • amenorrhea [Insufficient Evidence]
  • anemia, chemo-related [Insufficient Evidence]
  • angina [Insufficient Evidence]
  • anthracycline-induced cardiotoxicity [Insufficient Evidence]
  • aplastic anemia [Insufficient Evidence]
  • asthma [Insufficient Evidence]
  • beta-thalassemia [Insufficient Evidence]
  • breast CA [Insufficient Evidence]
  • cervical CA [Insufficient Evidence]
  • chronic fatigue syndrome [Insufficient Evidence]
  • cirrhosis [Insufficient Evidence]
  • CKD [Insufficient Evidence]
  • colorectal CA [Insufficient Evidence]
  • COPD [Insufficient Evidence]
  • diabetes mellitus [Insufficient Evidence]
  • diabetic nephropathy [Insufficient Evidence]
  • diabetic neuropathy [Insufficient Evidence]
  • diabetic retinopathy [Insufficient Evidence]
  • diarrhea, chemo-related [Insufficient Evidence]
  • fatigue, chemo-related [Insufficient Evidence]
  • fibromyalgia [Insufficient Evidence]
  • gastric CA [Insufficient Evidence]
  • hearing loss [Insufficient Evidence]
  • heart failure [Insufficient Evidence]
  • hepatitis B [Insufficient Evidence]
  • HIV/AIDS [Insufficient Evidence]
  • leukopenia, chemo-related [Insufficient Evidence]
  • IgA nephropathy [Insufficient Evidence]
  • lung CA [Insufficient Evidence]
  • membranous nephropathy [Insufficient Evidence]
  • menopausal symptoms [Insufficient Evidence]
  • MI [Insufficient Evidence]
  • myocarditis [Insufficient Evidence]
  • nausea/vomiting, chemo-related [Insufficient Evidence]
  • nephrotoxicity, chemo-related [Insufficient Evidence]
  • nephrotic syndrome [Insufficient Evidence]
  • obesity [Insufficient Evidence]
  • post-stroke fatigue [Insufficient Evidence]
  • SLE [Insufficient Evidence]
  • tinnitus [Insufficient Evidence]
  • URI [Insufficient Evidence]
  • UTI [Insufficient Evidence]
  • wound healing [Insufficient Evidence]

Copyright © 2026. All Rights Reserved. Republication or redistribution, including by framing or similar means, is prohibited without the prior written consent of copyright holder.

Select a medication above to begin.

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information